Merck, CCTG announce phase 2/3 trial of Keytruda plus chemotherapy improves OS vs chemotherapy alone to treat advanced malignant pleural mesothelioma

Merck, known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) announced that the phase 2/3 CCTG IND.227/KEYNOTE-483 trial evaluating Keytruda, Merck